Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Hemispherx Biopharma Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 111,000 135,000 161,000 213,000 150,000
Cost of Goods Sold (COGS) incl. D&A 1.32M 1.34M 1.04M 1.99M 1.23M
COGS excluding D&A 584,000 561,000 413,000 1.31M 543,000
Depreciation & Amortization Expense 740,000 780,000 630,000 683,000 691,000
Depreciation - 407,000 465,000 643,000 671,000
Amortization of Intangibles - 373,000 165,000 40,000 20,000
Gross Income (1.21M) (1.21M) (882,000) (1.78M) (1.08M)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense - 15.18M 13.41M 18.56M 15.91M
Research & Development - 7.61M 6.72M 9.51M 8.18M
Other SG&A - 7.57M 6.69M 9.06M 7.72M
Other Operating Expense - 0 0 0 0
Unusual Expense - (879,000) (2.49M) (94,000) 695,000
EBIT after Unusual Expense - 879,000 2.49M 94,000 (695,000)
Non Operating Income/Expense - 0 2.27M 1.33M 686,000
Non-Operating Interest Income - 2.38M 555,000 1.59M 791,000
Equity in Affiliates (Pretax) - 0 0 0 0
Interest Expense 0 11,000 41,000 24,000 16,000
Gross Interest Expense 0 11,000 41,000 24,000 159,000
Interest Capitalized - - - 0 143,000
Pretax Income - (13.14M) (9.02M) (17.35M) (16.23M)
Income Tax - 0 0 0 0
Income Tax - Current Domestic - 0 0 - -
Income Tax - Current Foreign - 0 0 - -
Income Tax - Deferred Domestic - 0 0 - -
Income Tax - Deferred Foreign - 0 0 - -
Income Tax Credits - 0 0 - -
Equity in Affiliates - 0 0 0 0
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income (7.18M) (13.14M) (9.02M) (17.35M) (16.23M)
Minority Interest Expense - 0 0 0 0
Net Income (7.18M) (13.14M) (9.02M) (17.35M) (16.23M)
Extraordinaries & Discontinued Operations - 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets - 0 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations - 0 0 0 0
Net Income After Extraordinaries (7.18M) (13.14M) (9.02M) (17.35M) (16.23M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common - (13.14M) (9.02M) (17.35M) (16.23M)
EPS (Basic) (0.07) (0.10) (0.07) (0.12) (0.10)
Basic Shares Outstanding 109.51M 134.02M 135.43M 141.02M 167.33M
EPS (Diluted) (0.07) (0.10) (0.07) (0.12) (0.10)
Diluted Shares Outstanding 109.51M 134.02M 135.43M 141.02M 167.33M
EBITDA - (15.61M) (13.67M) (19.66M) (16.3M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.